## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full text, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The study identifies three compounds (ChemBridge5963254, BDH33906706, ZINC000013607604) as potent inhibitors of TetR-family transcription regulators in Acinetobacter baumannii, using a multi-step in silico pipeline including shape-based screening, molecular docking, molecular dynamics simulations, MM/GBSA and MM/PBSA calculations, ADMET assessment, PAINS assay, and SIFT analysis. The authors claim these compounds show favorable binding, stable dynamics, and drug-like properties relative to reference compounds, and propose them as candidates for combating tetracycline resistance.
- **Visible evidence base** Abstract text only; no numerical data, figures, tables, or methodological details are provided
- **Missing materials affecting confidence** Full manuscript, all figures and tables, docking scores, simulation trajectories, ADMET data, compound structures, reference compound identities, and statistical analyses

## Reviewer
- **Overall assessment** The abstract presents a plausible computational workflow for identifying TetR-FTR inhibitors, but the evidence provided is insufficient to evaluate the validity of the core claims. The pipeline is described in broad terms without quantitative results, and the key conclusion that three compounds are "promising candidates" rests on unverifiable data. The work may be of interest to computational antibiotic discovery researchers, but the case is not established from the supplied material.
- **Who would be interested in the results, and why** Computational biologists and medicinal chemists working on antibiotic resistance, particularly those focused on Acinetobacter baumannii and TetR-family regulators. The methodological combination of shape screening, docking, and molecular dynamics could serve as a template for similar target-based virtual screening studies.
- **Major strengths** The study addresses a clinically relevant problem (multidrug-resistant A. baumannii) and targets a non-obvious protein class (TetR-FTRs) rather than the more commonly studied efflux pumps directly. The multi-layered in silico pipeline is comprehensive and includes standard validation steps such as PAINS filtering and ADMET assessment.
- **Major Concerns** The abstract lacks all quantitative evidence needed to assess the claims. No docking scores, binding free energies, simulation stability metrics, or ADMET values are reported. The selection of the three final compounds is not justified with comparative data. The biological relevance of the target and the functional link between TetR-FTR inhibition and resistance reversal is asserted but not demonstrated.
- **Minor Comments** The abstract uses imprecise language in places (e.g., "exert influence over" and "rigorously pruning") that could be tightened. The distinction between MM/GBSA and MM/PBSA is mentioned but their respective roles in the decision-making process are not clarified. The phrase "fulfilled all SIFT criteria" is vague without defining those criteria.
- **Technical failings that need to be addressed before the case is established** R1-M1 (no quantitative evidence), R1-M2 (target validation absent), R1-M3 (compound selection criteria unclear)
- **Assessment against Nature-style criteria** Originality: moderate, as the target class is underexplored but the methods are standard. Scientific importance: potentially high given the clinical urgency, but not demonstrated from the abstract. Interdisciplinary readership: limited, as the work is purely computational and would primarily appeal to specialists. Technical soundness: cannot be assessed without data. Readability for nonspecialists: the abstract is accessible but lacks context for why TetR-FTRs are a viable target.
- **Recommendation posture** Currently not established from the provided evidence. The abstract alone does not support the claims, and full data are required for any meaningful evaluation.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The abstract claims that the three compounds show "favorable glide scores, lower binding free energies, and interactions with crucial active site residue Hsd128-Mg(2+)" and "consistently exhibited stable binding" in molecular dynamics simulations.
- **Evidence pointer** Abstract text; location not provided
- **Concern** No numerical values are provided for any of the stated metrics. Glide scores, binding free energies (from MM/GBSA or MM/PBSA), and simulation stability measures (e.g., RMSD, RMSF, hydrogen bond occupancy) are all absent. The comparison to reference compounds is mentioned but no reference compound names or comparative values are given.
- **Why it matters** Without quantitative data, the reader cannot verify whether the observed values are actually favorable, whether the differences from reference compounds are meaningful, or whether the simulations were adequately converged. The core claim of inhibitor potency is entirely unsubstantiated.
- **Resolution test** Provide a table or figure with docking scores, binding free energies, and simulation metrics for the three compounds and at least one reference compound, with appropriate statistical measures.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Biological relevance
- **Claim pointer** The abstract states that TetR-FTRs "coordinate functions of tetracycline efflux pump proteins (TetA and TetR) and exert influence over metabolic pathways, quorum sensing, and biofilm formation," implying that inhibiting them will combat tetracycline resistance.
- **Evidence pointer** Abstract text; location not provided
- **Concern** The functional link between TetR-FTR inhibition and resistance reversal is asserted but not supported by any experimental or even computational evidence in the abstract. No data show that the identified compounds actually disrupt TetR-FTR function, alter TetA/TetR expression, or reduce resistance in any assay.
- **Why it matters** The stated goal is "combating tetracycline resistance," but the study is purely computational and stops at binding predictions. Without any functional validation, the relevance of the identified compounds to the clinical problem remains speculative.
- **Resolution test** Include at least one experimental validation (e.g., MIC assays, efflux inhibition, or gene expression analysis) or clearly state that the work is hypothesis-generating and requires experimental follow-up.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Methodological transparency
- **Claim pointer** The abstract describes a multi-step pipeline: "Swiss Similarity search yielded 2178 compounds," "PAINS analysis rigorously pruning the list, eliminating 14 false positive hits," and "SIFT approach discriminated closely related interacting compounds into three distinct clusters."
- **Evidence pointer** Abstract text; location not provided
- **Concern** The criteria for compound selection at each step are not defined. What thresholds were used for Swiss Similarity scores? What constitutes a "false positive" in the PAINS analysis? What are the "SIFT criteria" that the three final compounds fulfilled? The number of compounds at each stage is given, but the logic for progression is opaque.
- **Why it matters** Reproducibility is a core requirement for computational studies. Without explicit selection criteria, the pipeline cannot be replicated or assessed for potential biases that may have influenced the final compound choice.
- **Resolution test** Provide a detailed methods section with specific thresholds, scoring functions, and decision rules for each filtering step, ideally in a flowchart or supplementary table.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract language
- **Evidence pointer** Abstract text; location not provided
- **Issue** Phrases such as "exert influence over" and "rigorously pruning" are imprecise and could be interpreted in multiple ways.
- **Required correction** Replace with specific descriptions, e.g., "regulate expression of" and "filtered using PAINS criteria to remove compounds with pan-assay interference patterns."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Methodological distinction
- **Affected element** MM/GBSA and MM/PBSA usage
- **Evidence pointer** Abstract text; location not provided
- **Issue** Both MM/GBSA and MM/PBSA are listed as separate techniques, but their respective roles in the analysis are not explained. It is unclear whether both were used for the same purpose or for different stages.
- **Required correction** Clarify whether one was used for ranking and the other for validation, or specify the different contexts in which each was applied.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Terminology
- **Affected element** "SIFT criteria"
- **Evidence pointer** Abstract text; location not provided
- **Issue** The term "SIFT" is used without definition. In structural biology, SIFT typically refers to "Sorting Intolerant From Tolerant" for mutation analysis, which does not match the described clustering application.
- **Required correction** Define the acronym in the abstract or use a more descriptive term, such as "structural interaction fingerprinting analysis."

## Risk / unsupported claims
- The claim that the three compounds are "promising candidates for addressing tetracycline resistance" is unsupported because no functional or resistance-related data are presented.
- The claim that the compounds interact with "crucial active site residue Hsd128-Mg(2+)" is unverifiable without structural figures or interaction diagrams.
- The claim that molecular dynamics simulations showed "stable binding" is unsupported without trajectory analysis metrics.
- The claim that the pipeline "rigorously" pruned false positives is unverifiable without defined criteria.
- The overall relevance of TetR-FTR inhibition to tetracycline resistance reversal is asserted but not demonstrated.